Comprehensive analysis of the main therapeutic effects and suitable groups of sotoracib (AMG 510)

Sotorasib (AMG 510) is an oral small molecule targeted drug that is a KRAS G12C inhibitor. KRAS G12C is a common driver mutation type in the KRAS gene, which is more common in non-small cell lung cancer (NSCLC) and some colorectal cancer patients. Sotoracib forms covalent binding to the KRAS G12C mutation site, locking the protein in an inactive state, thereby blocking downstream signaling pathways (such as the MAPK pathway) and effectively inhibiting tumor cell proliferation and survival. This mechanism makes it a representative drug for precision targeted therapy, bringing new treatment options to KRAS G12C positive patients who previously lacked effective targeting options.

In clinical application, sotoraxib is mainly used for patients with KRAS G12C mutation-positive advanced or metastatic non-small cell lung cancer. Multiple clinical studies have shown that this drug can achieve an objective response rate (ORR) of approximately 35%-40% in patients who have previously received chemotherapy or immunotherapy and have improved disease control. The control rate (DCR) exceeds 80%, and the duration of remission in some patients exceeds 6 months. Its efficacy is reflected in tumor shrinkage, symptom improvement, and quality of life improvement, and is of great significance for long-term maintenance of disease stability.

The groups suitable for the use of sotorasibu mainly include: 1.KRAS G12Cmutation-positive late-stage NSCLC patients, especially those who have previously received platinum-based chemotherapy or PD-1/PD-L1 immunotherapy with poor results; the second is some KRAS G12C colorectal cancer patients with positive mutations can be used as optional targeted drugs after standard treatment fails; third, patients whose physical condition allows oral targeted drug treatment and whose liver and kidney functions are basically normal. Genetic testing is required before use to confirm the KRAS G12C mutation status to ensure the accuracy and efficacy of the drug.

In terms of safety, sotoraxib is generally well tolerated, with common adverse reactions including mild to moderate fatigue, diarrhea, abnormal liver function and mild changes in hematological indicators. Most adverse reactions can be managed through symptomatic treatment or dose adjustment without affecting the overall treatment plan. At the same time, because the drug targetsKRAS G12CIt has strong specificity, causes less damage to normal tissues, and is relatively safe for long-term use. Taken together, sotoracib provides a clear targeted treatment pathway for KRAS G12C positive patients, and is especially suitable as a treatment option for patients with advanced lung cancer and some colorectal cancers after standard treatments fail.

Reference link:https://www.drugs.com